Our End User License Agreement has been updated. Click here to learn more

×

Real-World Adherence

Adherence is the Key to Better Financial Outcomes1

 

Continuous glucose monitoring (CGM) is the gold standard of glycemic management,2 but low adherence rates have proven to limit its efficacy. 

  • Almost 25% of traditional CGM spend is wasted3
  • ~27% of traditional CGM users discontinue use after 1 year4
  • Only 63% of traditional CGM patients show real-world sensor wear time >70%.5-8
 

Optimal CGM adherence means to better outcomes 

 
  • 80% sensor use is associated with twice the HbA1c reduction.9
  • >90% adherence reduces healthcare costs, compared to traditional CGM wear time.10
    • €590 per patient per year less in emergency services 
    • €1,146 per patient per year less in outpatient services 

Product Whys — Adherence

Eversense Reduces Patient Burden and Improves Adherence

  • Long-term fully implantable sensor simplifies daily use by eliminating self-insertions
  • Water-resistant* transmitter can be removed without disturbing the sensor
  • Gentle hypoallergenic adhesive virtually eliminates skin irritation risk
Men hiking with Eversense

Learn more on how Eversense long-term CGM is improving adherence and outcomes.

Connect with Us

1 Bansal, M, et al. Appl Health Econ Health Policy (2018) 16: 675. 2 Endocrine Society Clinical Practice Guideline. Published September 2016. 3 Yu, S., Diabetes Technology & Therapeutics, 20(6), 420-427. 4 T1D Exchange; Why Do Some People with T1D Stop Using a Pump and CGM? 2016. 5 De Bock M. Journal of Diabetes Science and Technology. 2016;10(3):627-632. 6 McQueen RB. Endocr Pract 2014;20:1007–1015. 7 Picard S.Diabetes Technol Ther 2016; 18:127–135. 8 Charleer S. The J of Clin Endo & Metab, Volume 103, Issue 3, 1 March 2018,1224–1232. 9 Bergenstal RM. N Engl J Med 2010;363:311–320pmid:20587585. 10 Data on file. Senseonics 2019.

*Water resistant smart transmitter submerged up to 1 meter for up to 30 minutes. 

MKT-001297 Rev1

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.